Н. И. Микшис, П. Ю. Попова, А. П. Семакова, Владимир Кутырев
{"title":"西伯利亚有执照的疫苗和临床试验药物","authors":"Н. И. Микшис, П. Ю. Попова, А. П. Семакова, Владимир Кутырев","doi":"10.36233/0372-9311-2017-4-112-126","DOIUrl":null,"url":null,"abstract":"High pathogenicity of anthrax agent combined with unique insensitivity of its spore forms to environmental stresses class it among extremely dangerous biological agents. Registered and effectively used anthrax vaccines made invaluable contribution to the improvement of epidemiological situation around the world. Nevertheless, neglect of non-specific prophylaxis may result in dramatic scenarios and require large-scale measures on rectification of the consequences. Efforts on the development of next-generation vaccines are aimed at safety build-up, decrease in frequency of administration, and enhancement of manufacturing technologies. The review contains the key information on licensed anthrax vaccines designed for medical use, both in the territory of the Russian Federation and abroad. Among multiple experimental developments emphasized have been preparations manufactured by various biopharmaceutical companies in compliance with GMP standards, at different phases of clinical trials in 2016.","PeriodicalId":24020,"journal":{"name":"Zhurnal mikrobiologii, epidemiologii, i immunobiologii","volume":"14 1","pages":"112-126"},"PeriodicalIF":0.0000,"publicationDate":"2017-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"ЛИЦЕНЗИРОВАННЫЕ СИБИРЕЯЗВЕННЫЕ ВАКЦИНЫ И ЭКСПЕРИМЕНТАЛЬНЫЕ ПРЕПАРАТЫ НА СТАДИИ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ\",\"authors\":\"Н. И. Микшис, П. Ю. Попова, А. П. Семакова, Владимир Кутырев\",\"doi\":\"10.36233/0372-9311-2017-4-112-126\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"High pathogenicity of anthrax agent combined with unique insensitivity of its spore forms to environmental stresses class it among extremely dangerous biological agents. Registered and effectively used anthrax vaccines made invaluable contribution to the improvement of epidemiological situation around the world. Nevertheless, neglect of non-specific prophylaxis may result in dramatic scenarios and require large-scale measures on rectification of the consequences. Efforts on the development of next-generation vaccines are aimed at safety build-up, decrease in frequency of administration, and enhancement of manufacturing technologies. The review contains the key information on licensed anthrax vaccines designed for medical use, both in the territory of the Russian Federation and abroad. Among multiple experimental developments emphasized have been preparations manufactured by various biopharmaceutical companies in compliance with GMP standards, at different phases of clinical trials in 2016.\",\"PeriodicalId\":24020,\"journal\":{\"name\":\"Zhurnal mikrobiologii, epidemiologii, i immunobiologii\",\"volume\":\"14 1\",\"pages\":\"112-126\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhurnal mikrobiologii, epidemiologii, i immunobiologii\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36233/0372-9311-2017-4-112-126\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhurnal mikrobiologii, epidemiologii, i immunobiologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36233/0372-9311-2017-4-112-126","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
ЛИЦЕНЗИРОВАННЫЕ СИБИРЕЯЗВЕННЫЕ ВАКЦИНЫ И ЭКСПЕРИМЕНТАЛЬНЫЕ ПРЕПАРАТЫ НА СТАДИИ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ
High pathogenicity of anthrax agent combined with unique insensitivity of its spore forms to environmental stresses class it among extremely dangerous biological agents. Registered and effectively used anthrax vaccines made invaluable contribution to the improvement of epidemiological situation around the world. Nevertheless, neglect of non-specific prophylaxis may result in dramatic scenarios and require large-scale measures on rectification of the consequences. Efforts on the development of next-generation vaccines are aimed at safety build-up, decrease in frequency of administration, and enhancement of manufacturing technologies. The review contains the key information on licensed anthrax vaccines designed for medical use, both in the territory of the Russian Federation and abroad. Among multiple experimental developments emphasized have been preparations manufactured by various biopharmaceutical companies in compliance with GMP standards, at different phases of clinical trials in 2016.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
